An RP-HPLC method was developed and validated for the simultaneous quantification of Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz in both bulk and pharmaceutical formulations. The chromatographic separation of Emtricitabine, Tenofovir Disoproxil Fumarate and Efavirenz was achieved on a YMC PACK ODS AQ (150 mm x 4.6 mm ID, 5 µm), Waters Alliance HPLC system equipped with 2998 Photo Diode Array (PDA) detector and Empower 2 software. The optimized mobile phase was consisted of potassium dihydrogen phosphate buffer (pH adjusted to 4.5 with OPA) and Acetonitrile (40:60, v/v). The flow rate was 1mL / min and effluents were monitored at 257nm. Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz were found to have retention times of 2.185 min, 4.848 min, and 15.682 min, respectively. The resolution values for the two adjacent peaks were determined to be 4.15 and 12.08. The linearity was found in the concentration range of 35-65ppm with correlation coefficient was 0.999. The regression equation of Emtricitabine, Tenofovir Disoproxil Fumarate and Efavirenz was found to be Y = 31987x + 2256, Y = 17161x + 4100 and Y = 54966x + 9250 respectively. LOD values were found to be 0.24ppm for Emtricitabine, 0.78ppm for Tenofovir Disoproxil Fumarate and 0.56ppm for Efavirenz and LOQ values were found to be 0.72ppm for Emtricitabine, 2.37ppm for Tenofovir Disoproxil Fumarate and 1.68ppm for Efavirenz. The percentage recoveries were between 99.64 %-99.97 % for Emtricitabine, 100.04 %-100.08 % for Tenofovir Disoproxil Fumarate and 99.92 %-100.05 % for Efavirenz respectively. The proposed method was effectively employed to quantitatively assess Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz in bulk and pharmaceutical formulations in accordance with the ICH guidelines.